VENUS REMEDIES
VENUSREMVerifiedVENUS REMEDIES is a publicly traded security listed on the BSE exchange.
Stock Snapshot & Key Numbers — VENUS REMEDIES
Verified Daily CloseOfficial closing price, 1-year price range, valuation multiples, and market value from exchange records.
VENUS REMEDIES (VENUSREM) is a Indian equity security listed on the BSE with ISIN BSE:526953. As of the last recorded market session on Close on 16 Oct 2026, the stock closed at ₹1642.40, recording a +78.20 (+5.00%) advance from its previous close of ₹1564.20. Over the trailing 52-week trading cycle, VENUSREM has traded between a 52-week low of ₹434.75 and a 52-week high of ₹1966.50, establishing its annual trading channel. In historical performance, VENUS REMEDIES has gained 257.2% over the past 1 year. Period returns across standard measurement intervals include: 1-week: +0.71%, 1-month: +7.29%, 6-month: +58.06%, 1-year: +257.2%, 3-year: +501.39%, 5-year: +233.65%. Daily reported trading volume reached 3,361 equity shares. On key valuation multiples as of 11 Oct 2026, the company trades at a trailing price-to-earnings (P/E) multiple of 18.8x and a price-to-book (P/B) ratio of 3.3x, with a trailing dividend yield of 0.61%. Its market capitalization stands at ₹2,179.82 Cr. The company is categorized under the Diversified Indian Equities sector and Public Market Listed Security industry within the Indian equities universe.
Price Chart
Trading Multiples & Ranges
Price boundaries and liquidity distribution.
Past Price Win/Loss Odds (1-Week, 1-Month, 3-Month)
How often this stock rose, stayed flat, or fell over past 21-day holding periods (based on historical data, not a future prediction).
How Outside Factors Affect This Stock (Market, Crude Oil & Currency)
How closely this stock moved with the broader market index, crude oil, and the exchange rate over the past year.
| Factor / Benchmark | 1Y Beta (Sensitivity) | 1Y Correlation (-1 to +1) | What This Means |
|---|---|---|---|
| NIFTY 50 | +0.87 | +0.22 | Trailing 1Y historical sensitivity: a 1% move in NIFTY 50 coincided with a +0.87% co-movement (correlation: 0.22). Descriptive historical relationship, not predictive. |
| USD / INR | -0.23 | -0.03 | Trailing 1Y historical sensitivity: a 1% move in USD / INR coincided with a -0.23% co-movement (correlation: -0.03). Descriptive historical relationship, not predictive. |
| Brent Crude Oil | +0.00 | +0.00 | Trailing 1Y historical sensitivity: a 1% move in Brent Crude Oil coincided with a +0.00% co-movement (correlation: 0.00). Descriptive historical relationship, not predictive. |
| US 10Y Treasury Yield | -0.14 | -0.04 | Trailing 1Y historical sensitivity: a 1% move in US 10Y Treasury Yield coincided with a -0.14% co-movement (correlation: -0.04). Descriptive historical relationship, not predictive. |
How to read Beta & Correlation ( Beta > 1 = wider swings than market; < 1 = calmer )▾
Sensitivities measure historical 1-year regression beta and correlation across paired daily trading sessions over the past 252 trading days. Past relationships can shift over time and do not guarantee future co-movement.
Trailing Returns Breakdown
Calendar-aligned historical percentage performance across standard market windows.
| Period | Start Price | Current Price | Return (%) |
|---|---|---|---|
| 1 Week | ₹1,630.75 | ₹1,642.40 | +0.71% |
| 15 Days | ₹1,784.40 | ₹1,642.40 | -7.96% |
| 1 Month | ₹1,530.85 | ₹1,642.40 | +7.29% |
| 3 Months | ₹1,799.45 | ₹1,642.40 | -8.73% |
| 6 Months | ₹1,039.10 | ₹1,642.40 | +58.06% |
| 1 Year | ₹459.80 | ₹1,642.40 | +257.20% |
| 3 Years | ₹273.10 | ₹1,642.40 | +501.39% |
| 5 Years | ₹492.25 | ₹1,642.40 | +233.65% |
Price Swings & Biggest Historical Drops
How much this stock typically fluctuates and its largest peak-to-bottom drops over 1 and 5 years.
Calendar-Year Historical Performance
Annual performance breakdown comparing first and last closing sessions of each calendar year.
| Calendar Year | Start Close | End Close | Annual Return | Trajectory Bar |
|---|---|---|---|---|
| CY 2026 | ₹756.30 | ₹1,642.40 | +117.2% | |
| CY 2025 | ₹318.10 | ₹767.00 | +141.1% | |
| CY 2024 | ₹405.60 | ₹320.15 | -21.1% | |
| CY 2023 | ₹178.55 | ₹405.95 | +127.4% | |
| CY 2022 | ₹412.35 | ₹181.15 | -56.1% | |
| CY 2021 | ₹492.25 | ₹409.60 | -16.8% |
Historical Investment Simulator
Factual simulation of past returns in VENUS REMEDIES (VENUSREM) using real recorded closing prices.
Corporate Actions & Distributions
Historical record of dividend payouts and share split adjustments for VENUSREM.
Dividend Distributions (1)
| Ex-Date | Dividend Amount |
|---|---|
| 7 Aug 2026 | ₹10.00 per share |
Stock Splits & Multipliers (0)
No stock split adjustments recorded.
Recent News & Official Exchange Announcements
Official exchange filings, order wins, and company updates. Click any announcement to see how it affects the business on the right.
Venus Remedies Q4 Profit Surges 126% to ₹47.5 Cr as Margins Expand 956 Bps - Sahi
Venus Remedies Q4 Profit Surges 126% to ₹47.5 Cr as Margins Expand 956 Bps Sahi
Venus Remedies (NSE:VENUSREM) Secures Five Global Drug Approvals - Kalkine India
Venus Remedies (NSE:VENUSREM) Secures Five Global Drug Approvals Kalkine India
Venus Remedies Ltd. Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Venus Remedies Ltd. Financials – Balance Sheet, Profit & Loss, Cash Flow Value Research
Venus Remedies Files Newspaper Notice on Special Window for Physical Share Transfers - scanx.trade
Venus Remedies Files Newspaper Notice on Special Window for Physical Share Transfers scanx.trade
Venus Remedies Consolidated March 2026 Net Sales at Rs 259.40 crore, up 33.05% Y-o-Y - Moneycontrol.com
Venus Remedies Consolidated March 2026 Net Sales at Rs 259.40 crore, up 33.05% Y-o-Y Moneycontrol.com
Why This Matters for the Business
Plain-English breakdown of how the selected announcement connects to revenue, costs, and business drivers.
Financial performance outpaced historical baseline, driving operating leverage and valuation re-rating.
- •Transaction / financial magnitude identified at ₹47.5 Cr
- •Direct quantitative change registered at 126%
- •Financial performance and operating margins expanded ahead of consensus projections
Volume throughput absorbs fixed manufacturing plant overheads, supporting operating EBITDA margins and cash generation across diversified indian equities units.
Identified project outlay of ₹47.5 Cr secures forward multi-quarter top-line visibility.
At-a-Glance Health & Momentum Check
Recent exchange filings and reported financial statements show healthy alignment between revenue growth, operating cash flow, and improving profit margins.
Peer & Sector Comparison — Next Research Steps
Exit points and comparative equity universe: same-sector peers, shared macro sensitivity betas, and your watchlist.
Common Questions About VENUS REMEDIES (VENUSREM)
Key facts on VENUSREM share price, historical returns, valuation ratios, and past SIP performance.
What is the current share price and 52-week range of VENUS REMEDIES (VENUSREM)?
As of 16 Oct 2026, the official closing share price of VENUS REMEDIES (VENUSREM) on BSE is ₹1,642.40 (+5.00% vs the previous close). Over the past 52 weeks, VENUSREM has traded between a low of ₹434.75 and a high of ₹1,966.50, with a reported market capitalization of ₹2,179.82 Cr.
What are the historical returns of VENUS REMEDIES (VENUSREM)?
Based on split-adjusted closing prices through 16 Oct 2026, VENUS REMEDIES (VENUSREM) recorded the following trailing price returns: 1 Week: +0.71% (from ₹1,630.75 to ₹1,642.40); 15 Days: -7.96% (from ₹1,784.40 to ₹1,642.40); 1 Month: +7.29% (from ₹1,530.85 to ₹1,642.40); 3 Months: -8.73% (from ₹1,799.45 to ₹1,642.40); 6 Months: +58.06% (from ₹1,039.10 to ₹1,642.40); 1 Year: +257.20% (from ₹459.80 to ₹1,642.40); 3 Years: +501.39% (from ₹273.10 to ₹1,642.40); 5 Years: +233.65% (from ₹492.25 to ₹1,642.40). Past performance reflects historical exchange records and does not predict future returns.
What is the P/E ratio, P/B ratio, and dividend yield of VENUS REMEDIES (VENUSREM)?
VENUS REMEDIES (VENUSREM) currently trades at a trailing Price-to-Earnings (P/E) ratio of 18.8x, a Price-to-Book (P/B) ratio of 3.3x, and a trailing 12-month dividend yield of 0.61%. It operates in the Diversified Indian Equities sector (Public Market Listed Security).
How much would a past lump-sum or monthly SIP investment in VENUSREM have grown?
Based on historical closing prices for VENUS REMEDIES (VENUSREM): A one-time lump-sum investment of ₹1,00,000.00 held for 5 years would be worth ₹3,33,651.60 (+233.7% total return, 27.3% CAGR), while a monthly SIP of ₹10,000.00 over 5 years (total invested: ₹6,10,000.00) would be worth ₹30,41,437.48 (+398.6% absolute return). You can test custom amounts and holding periods in the interactive calculator above.
Official Corporate Perspective
Authorized Investor Relations officers may submit authenticated context or coordinate with our research team.